MEDEZE 9-Month Revenue Surpasses 500 Million Baht

MGR Online•Economy•52m ago

Reader Briefing

Medeze Group reported total revenues of 506.62 million baht for the first nine months of 2026, driven by growth in adipose-derived stem cell services.

•Medeze Group earned 506.62 million baht in revenue and 101.84 million baht in net profit during the first nine months of 2026.
•The company announced an interim cash dividend of 0.08 baht per share.
•Medeze Group is the only private entity in Thailand to receive the GMDP PIC/S Certificate for Investigational Cell Therapy Product for human adipose tissue cell therapy for clinical research.
•The company is expanding its service base into the adult market to reduce reliance on the newborn market.

Overview

•Medeze Group recorded total revenue of 165.17 million baht and net profit of 27.29 million baht for the third quarter of 2026.
•Revenue from adipose-derived stem cells reached a new high of 40 million baht in the third quarter of 2026 and 104 million baht for the first nine months of 2026.
•Medeze Group set the ex-dividend (XD) date for November 24, 2026, with the dividend payment scheduled for December 9, 2026.
•Medeze Group received Cell Bank Standard certification from the Department of Medical Sciences in the second quarter of 2026.
•Medeze Group passed the GMDP PIC/S assessment by the Food and Drug Administration in the third quarter of 2026.
•Medeze Group is conducting research on treating knee osteoarthritis and slowing facial skin aging to register stem cell drugs from one's own fat.
•Medeze Group is expanding adult market services to include adipose stem cells, hair follicle cells, and NK cells to address healthcare trends and an aging society.

Full article content is available on the original source.

Read on MGR Online (Thai Version)View in Google Translate

Source: MGR Online (Original)

View Original Article

Key Entities

Organization

Medeze Group Public Company Limited(บริษัท เมดีซ กรุ๊ป จำกัด (มหาชน))

A medical innovation company also referred to as MEDEZE that provides cell bank and stem cell services.

Food and Drug Administration(สำนักงานคณะกรรมการอาหารและยา)ℹ️

The agency that assessed Medeze Group for the GMDP PIC/S standard.

Department of Medical Sciences(กรมวิทยาศาสตร์การแพทย์)

The agency that certified Medeze Group's Cell Bank Standard.

BOI

The investment promotion agency providing tax incentives for part of Medeze Group's profits.

Person

Dr. Weerapon Khemarangsan(นายแพทย์วีรพล เขมะรังสรรค์)

The Chief Executive Officer of Medeze Group Public Company Limited.